POXEL SA: Poxel Reports Financial Results for Full Year 2021

Company reports revenues of EUR 13.4 million for the year ended December 31, 2021 As of December 31, 2021, cash and cash equivalents were EUR 32.3 million (USD 36.6 million) TWYMEEG

Related Keywords

New York , United States , Taiwan , Japan , Tokyo , Paris , France General , France , United Kingdom , China , Boston , Massachusetts , South Korea , London , City Of , Kobe , Hyogo , French , Japanese , Sumitomo Dainippon Pharma , Arthur Rouill , Thomas Kuhn , Merck Serono , Enregistrement Universel , Quentin Durand , European Renal Association Congress , Early Stage Development , Drug Administration , Leukodystrophy Charity , Meeting Of The Japanese Diabetes Society , Life Sciences Conference , Clinical Development Updates , United Leukodystrophy Foundation , Financial Press , Board Of Directors The Company , Track Designation , Fast Track , Diabetes Care , Diabetes Obesity , Multicenter Phase , Scientific Advisory Board , Alex The Leukodystrophy Charity , Corporate Social Responsibility , Executive Vice President , Chief Legal Officer , Fast Track Designation , Full Year , Following Upcoming , Japanese Diabetes Society , Renal Association Congress , Global Healthcare Conference , Sciences Conference , Financial Press Release , First Quarter , Japan Poxel , Sumitomo Dainippon , Southeast Asian , Euronext Paris , Relations Communication Senior Director , Vice President , Investor Relations Communication , Poxel , Troxel , Reports , Financial , Results , Bull , Ear , 021 , Rovides , Corporate , Update ,